ArticleACS medicinal chemistry letters2018
Targeting Tumor Associated Carbonic Anhydrases IX and XII: Highly Isozyme Selective Coumarin and Psoralen Inhibitors.
Article in ACS medicinal chemistry letters, 2018. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 22 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
22 citing papers in PubMed, 50 citations in OpenAlex.
- Chromones as Nonclassical Inhibitors of Carbonic Anhydrase IX and XII Isoforms: Probing Chromone-Based Derivatives.Archiv der Pharmazie · 2026Article
- Drug Design of Carbonic Anhydrase Inhibitors.Sub-cellular biochemistry · 2026Review
- Unraveling the Potential of Amino‑, Acylamino‑, and Ureido-Substituted 3ACS medicinal chemistry letters · 2025Article
- Investigation on Human Carbonic Anhydrase IX and XII Inhibitory Activity and A549 Antiproliferative Activity of a New Class of Coumarinamides.Pharmaceuticals (Basel, Switzerland) · 2025Article
- Pharmaceutical Design and Structure-activity Relationships of Psoralen and Derivatives.Current pharmaceutical design · 2025Review
- New Structural Features of Isatin Dihydrothiazole Hybrids for Selective Carbonic Anhydrase Inhibitors.ACS medicinal chemistry letters · 2024Article
- 2H-chromene and 7H-furo-chromene derivatives selectively inhibit tumour associated human carbonic anhydrase IX and XII isoforms.Journal of enzyme inhibition and medicinal chemistry · 2023Article
- Design, synthesis and fungicidal evaluation of novel psoralen derivatives containing sulfonohydrazide or acylthiourea moiety.Molecular diversity · 2023Article
- Potential Biochemical Pesticide-Synthesis of Neofuranocoumarin and Inhibition the Proliferation ofToxins · 2022Article
- Synthesis, Biological Evaluation, andACS omega · 2022Article
- Novel Insights on Human Carbonic Anhydrase Inhibitors Based on Coumalic Acid: Design, Synthesis, Molecular Modeling Investigation, and Biological Studies.International journal of molecular sciences · 2022Article
- Selective inhibition of carbonic anhydrase IX and XII by coumarin and psoralen derivatives.Journal of enzyme inhibition and medicinal chemistry · 2021Article
- Thiazole Ring-A Biologically Active Scaffold.Molecules (Basel, Switzerland) · 2021Review
- Synthesis, computational studies and assessment ofJournal of enzyme inhibition and medicinal chemistry · 2020Article
- Coumarins fromJournal of enzyme inhibition and medicinal chemistry · 2020Article
- Coumarin carbonic anhydrase inhibitors from natural sources.Journal of enzyme inhibition and medicinal chemistry · 2020Review
- Carbonic anhydrase modulation of emotional memory. Implications for the treatment of cognitive disorders.Journal of enzyme inhibition and medicinal chemistry · 2020Article
- Anticancer Potential of Furanocoumarins: Mechanistic and Therapeutic Aspects.International journal of molecular sciences · 2020Review
- Exploring new structural features of the 4-[(3-methyl-4-aryl-2,3-dihydro-1,3-thiazol-2-ylidene)amino]benzenesulphonamide scaffold for the inhibition of human carbonic anhydrases.Journal of enzyme inhibition and medicinal chemistry · 2019Article
- Extending the Inhibition Profiles of Coumarin-Based Compounds Against Human Carbonic Anhydrases: Synthesis, Biological, and In Silico Evaluation.Molecules (Basel, Switzerland) · 2019Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
16 authors at 5 institutions in 1 country.
Funding
No grant is acknowledged in the PubMed record.
Abstract
A small library of psoralen carboxylic acids and their corresponding benzenesulfonamide derivatives were designed and synthesized to evaluate their activity and selectivity toward tumor associated human carbonic anhydrase (hCA) isoforms IX and XII. Both psoralen acids and sulfonamides exhibited potent inhibition of IX and XII isozymes in the nanomolar concentration range. However, psoralen acids resulted as the most selective in comparison with the corresponding benzenesulfonamide derivatives. Our data indicate that the psoralen scaffold is a promising starting point for the design of highly selective tumor associated hCA inhibitors.
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.